Charles River Laboratories International, Inc. $CRL Shares Acquired by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 330.0% during the third quarter, Holdings Channel.com reports. The fund owned 10,750 shares of the medical research company’s stock after purchasing an additional 8,250 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Charles River Laboratories International were worth $3,171,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its position in Charles River Laboratories International by 440.4% during the third quarter. Maryland State Retirement & Pension System now owns 14,395 shares of the medical research company’s stock valued at $4,247,000 after buying an additional 11,731 shares in the last quarter. Lisanti Capital Growth LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter worth about $1,831,000. Lido Advisors LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $1,205,000. New York Life Investment Management LLC raised its holdings in Charles River Laboratories International by 371.3% in the third quarter. New York Life Investment Management LLC now owns 61,506 shares of the medical research company’s stock valued at $18,145,000 after acquiring an additional 48,455 shares in the last quarter. Finally, AlphaCore Capital LLC lifted its position in shares of Charles River Laboratories International by 222.4% during the third quarter. AlphaCore Capital LLC now owns 5,184 shares of the medical research company’s stock worth $1,529,000 after purchasing an additional 3,576 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL opened at $342.81 on Thursday. The stock has a fifty day moving average of $309.32 and a 200-day moving average of $227.05. The firm has a market capitalization of $16.43 billion, a P/E ratio of 376.71, a PEG ratio of 3.13 and a beta of 1.36. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $379.63. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. Charles River Laboratories International’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.43 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. Deutsche Bank increased their price objective on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Morgan Stanley lifted their price target on Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday, August 10th. Finally, Royal Bank Of Canada boosted their price objective on Charles River Laboratories International from $322.00 to $352.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $308.17.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Shannon Parisotto sold 2,156 shares of the business’s stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This represents a 30.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 63,352 shares of company stock valued at $20,291,281. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.